MS5 Antibody

What is the MS5 antibody and how was it originally developed?

MS5 is a human single-chain variable fragment (scFv) antibody that was identified through sequential affinity selection against a panel of human cancer cell lines. The antibody fragment was isolated from a phage display library and demonstrated binding capacity to both solid and blood cancer cells. For therapeutic applications, MS5 scFv was engineered by fusion to the human IgG1 Fc domain to generate the MS5-Fc fusion antibody with enhanced effector functions .

The development process involved:

• Creation of a human scFv antibody library

• Sequential affinity selection against multiple cancer cell lines

• Identification of MS5 as binding to common tumor antigens

• Engineering of MS5-Fc fusion by adding the human IgG1 Fc domain

This approach represents a significant advantage in therapeutic antibody development, as it allows for the identification of antibodies with pan-cancer abilities that can be widely applicable across multiple malignancies .

What are the primary mechanisms of action for MS5-Fc antibody against cancer cells?

MS5-Fc antibody demonstrates multiple mechanisms of action against cancer cells:

The ability of MS5-Fc to induce cell surface redistribution without internalization is particularly significant as it maintains the accessibility of the Fc domain to immune effector cells, potentially enhancing its therapeutic efficacy compared to antibodies that undergo rapid internalization .

How does the stability profile of MS5-Fc antibody influence its potential clinical applications?

In vitro stability studies demonstrated that MS5-Fc antibody maintains approximately 60% of its initial intact form after 6 days of incubation in human serum . This stability profile has several implications for clinical applications:

• The relatively extended stability in human serum suggests potential for sustained therapeutic activity following administration

• The stability data provides critical information for dosing frequency considerations in clinical trials

• Maintenance of structural integrity correlates with preserved functional activity over time

• The stability profile compares favorably with other therapeutic antibodies in development

What strategies can be employed to enhance the Fc-mediated effector functions of MS5 antibody?

Several engineering strategies could enhance the Fc-mediated effector functions of MS5 antibody:

• Point mutations in the Fc region:

  • Specific mutations such as DLE (Ser239Asp/Ile332Glu/Ala330Leu) can improve ADCC activity

  • Mutations that improve binding affinity to specific FcγRs, such as FcγRIIIa, can enhance effector functions

  • Combinations of mutations like Phe243Leu, Arg292Pro, Tyr300Leu, Val305Ile, and Pro396Leu have shown improved affinities for activating Fc receptors without increasing binding to inhibitory receptors

• Glycoengineering approaches:

  • Production of afucosylated antibodies by expressing in cells with fucosyltransferase knocked out

  • Afucosylated antibodies exhibit up to 50-fold more potent ADCC than fucosylated versions

• Cross-isotype antibody engineering:

  • Creating chimeric Fc regions that combine elements of different antibody isotypes

  • Exchange of IgG1 CH2 α1 loop residues 245-258 and CH3 domain with IgA regions creates antibodies capable of binding to both FcγRI and FcαRI

  • This approach enables recruitment of diverse effector cells to target cells

• Half-life extension modifications:

  • Introduction of Met428Leu and Asn434Ser mutations (LS mutations) can improve binding to FcRn and extend antibody half-life

  • Unlike some other half-life extending mutations, LS mutations do not significantly reduce ADCC activity

• Dual Fc architecture:

  • Novel "2Fc" antibody designs containing two Fc domains in addition to the normal two Fab domains

  • This architecture enhances avidity for Fc receptors, resulting in decreased dissociation rates and increased apparent affinity

  • Enables simultaneous binding to multiple Fc receptors, potentially enhancing effector functions

These engineering approaches could significantly enhance the therapeutic potential of MS5 antibody by improving its ability to engage immune effector mechanisms and extending its pharmacokinetic profile.

What is the role of inhibitory Fcγ receptors in the activity of agonistic antibodies like MS5-Fc?

Research on agonistic antibodies targeting death receptors has revealed a critical and somewhat counterintuitive role for inhibitory Fcγ receptors:

Agonistic antibodies to apoptosis-inducing tumor necrosis factor receptors (TNFRs), such as death receptor 5 (DR5), have an absolute requirement for the coengagement of the inhibitory Fcγ receptor, FcγRIIB, for optimal in vivo apoptotic and antitumor activities . This finding has significant implications for the design and optimization of therapeutic antibodies like MS5-Fc:

• Anti-DR5 antibodies with weak FcγRIIB binding are compromised in their proapoptotic and antitumor activities in colon and breast carcinoma models

• Enhancing FcγRIIB engagement increases apoptotic and antitumor potency

• This requirement for FcγRIIB coengagement appears to be a common feature for optimal biological effects of agonistic anti-TNFR antibodies

For antibodies like MS5-Fc, this suggests that engineered variants with optimized binding to FcγRIIB might demonstrate enhanced therapeutic activity, particularly if MS5's target receptors share signaling characteristics with TNFRs. Engineering strategies that balance engagement of activating and inhibitory Fcγ receptors could therefore be crucial for maximizing therapeutic efficacy .

How might tumor microenvironment factors influence MS5-Fc antibody efficacy?

The tumor microenvironment (TME) contains multiple elements that could significantly impact MS5-Fc antibody efficacy:

• Myeloid-derived suppressor cells (MDSCs):

  • MDSCs accumulate in various tumor types and express high levels of death receptor 5 (DR5)

  • Targeting DR5 with agonistic antibodies can selectively deplete MDSCs and promote T-cell antitumor responses

  • The presence of MDSCs in tumors may influence MS5-Fc efficacy if its target is expressed on these immunosuppressive cells

• Immune cell infiltration:

  • MS5-Fc antitumor effects are associated with infiltration of macrophages and NK cells into tumor tissues

  • Pre-existing immune cell infiltration patterns may predict response to MS5-Fc therapy

  • Strategies to enhance immune cell infiltration could potentially synergize with MS5-Fc treatment

• Expression of target antigens:

  • Heterogeneous expression of MS5 target antigens within tumors could limit efficacy

  • Tumor microenvironment conditions (hypoxia, acidosis) may alter expression of target antigens

  • Dynamic changes in target expression during treatment could influence long-term efficacy

• Combination therapy opportunities:

  • Combining MS5-Fc with agents that target the immunosuppressive TME could enhance efficacy

  • For example, the combination of agonistic anti-DR5 antibody (MD5-1) with anti-PD-L1 antibody showed synergistic antitumor effects in gastric and colon tumor-bearing mice

  • Such combinations resulted in increased intratumoral CD8+ T-cell infiltration and activation

Understanding these TME interactions will be crucial for optimizing MS5-Fc antibody therapy and designing rational combination strategies to overcome resistance mechanisms.

What techniques are optimal for evaluating MS5 antibody binding characteristics?

Multiple complementary techniques can be employed to comprehensively evaluate MS5 antibody binding characteristics:

• Biolayer Interferometry (BLI):

  • Used to determine binding kinetics and affinity constants

  • Can measure association rate (kon), dissociation rate (koff), and dissociation constant (KD)

  • Example application: MO1 and MO2 antibodies showed high affinity with BA.2 spike RBD, with KD values of 3.3 nM and 2.0 nM, respectively

• Enzyme-Linked Immunosorbent Assay (ELISA):

  • Useful for screening antibody binding to target antigens

  • Can be used for epitope mapping and cross-reactivity studies

  • Example: Fragments antigen binding (Fabs) derived from antibody variable region genes were screened by ELISA in the identification of SARS-CoV-2 neutralizing antibodies

• Flow Cytometry:

  • Evaluates binding to cell surface targets in their native conformation

  • Can quantify binding intensity and determine percentage of positive cells

  • Particularly useful for heterogeneous cell populations

• Competition Assays:

  • Assess whether the antibody competes with natural ligands or other antibodies

  • Example: Competition between antibodies and human ACE2 was assessed to investigate neutralizing mechanisms

• Surface Plasmon Resonance (SPR):

  • Provides detailed kinetic information about antibody-antigen interactions

  • Can detect conformational changes upon binding

• In vitro Stability Assays:

  • Assess retention of binding capacity after exposure to various conditions

  • MS5-Fc stability was evaluated by incubation in human serum for 6 days

For comprehensive characterization, researchers should employ multiple complementary techniques to fully understand the binding properties of MS5 antibody under various conditions relevant to its potential therapeutic applications.

How can researchers effectively assess the immune effector functions induced by MS5-Fc?

Assessment of immune effector functions induced by MS5-Fc requires multiple specialized assays:

For in vivo assessment of MS5-Fc efficacy:

• Select appropriate xenograft models (as demonstrated with breast, lymphoma, and leukemia xenografts)

• Monitor tumor growth kinetics following antibody administration

• Analyze tumor tissues for immune cell infiltration

• Compare with established antibody therapies (e.g., rituximab for B-cell lymphomas)

• Consider survival endpoints in addition to tumor volume measurements

Comprehensive assessment should include both in vitro and in vivo methods to fully characterize the immune effector functions induced by MS5-Fc and their contribution to antitumor activity.

What approaches can be used to identify the specific target antigens recognized by MS5 antibody?

Identifying the specific target antigens recognized by MS5 antibody requires a systematic approach using multiple complementary techniques:

• Immunoprecipitation followed by Mass Spectrometry:

  • MS5 antibody can be used to immunoprecipitate its target from cancer cell lysates

  • Precipitated proteins are identified by mass spectrometry

  • Comparison across multiple cell lines can identify common targets

• Protein Microarray Screening:

  • MS5 binding to arrays containing thousands of human proteins

  • Identifies potential targets for further validation

  • Particularly useful for identifying cross-reactive targets

• Cell Surface Biotinylation:

  • Selective labeling of cell surface proteins followed by immunoprecipitation

  • Helps distinguish membrane proteins from intracellular targets

  • Relevant since MS5 binds to cell surface targets

• CRISPR/Cas9 Knockout Screens:

  • Genome-wide CRISPR screens to identify genes whose loss prevents MS5 binding

  • Can reveal both direct targets and proteins involved in target expression/processing

  • Validation of hits by individual gene knockout

• Domain/Epitope Mapping:

  • Generation of truncated or chimeric proteins to identify binding regions

  • Peptide arrays to identify linear epitopes

  • Mutagenesis studies to identify critical binding residues

• Competition Studies:

  • Competition with known ligands or antibodies with defined targets

  • Can provide insights into the functional significance of MS5 binding

  • Similar to approaches used for investigating neutralizing antibody mechanisms

• Cross-linker-based Approaches:

  • Photo-activatable cross-linkers coupled to MS5 to covalently capture interacting proteins

  • Enables identification of low-affinity or transient interactions

Combining these approaches provides a comprehensive strategy for definitively identifying the target antigens recognized by MS5 antibody across different cancer types, which is critical for understanding its mechanism of action and potential clinical applications.

What are the key considerations for engineering MS5 variants with enhanced therapeutic properties?

Engineering MS5 variants with enhanced therapeutic properties requires careful consideration of multiple factors:

• Fc Engineering Strategies:

  • Point mutations to enhance FcγR binding:

    • DLE mutations (Ser239Asp/Ile332Glu/Ala330Leu) can improve ADCC activity

    • Combinations like Phe243Leu, Arg292Pro, Tyr300Leu, Val305Ile, and Pro396Leu can improve activating receptor binding without increasing inhibitory receptor binding

  • Half-life extension modifications:

    • LS mutations (Met428Leu/Asn434Ser) improve FcRn binding and extend half-life without significantly reducing ADCC

  • Glycoengineering approaches:

    • Production in cells with modified glycosylation (e.g., afucosylated glycans) can enhance ADCC up to 50-fold

• Novel Antibody Architectures:

  • Dual Fc domain antibodies:

    • "2Fc" architecture with two Fc domains shows enhanced avidity for Fc receptors

    • Decreases dissociation rates and increases apparent affinity by 7- to 42-fold

  • Cross-isotype antibodies:

    • Chimeric Fc regions combining elements of different antibody classes (e.g., IgG/IgA)

    • Enables binding to multiple Fc receptor types and recruitment of diverse effector cells

• Binding Domain Optimization:

  • Affinity maturation of the variable regions through:

    • Directed evolution approaches (phage display with error-prone PCR)

    • Structure-guided design if target epitope is known

  • Consideration of binding kinetics (kon/koff) not just equilibrium affinity (KD)

• Format Considerations:

  • Bispecific formats to engage multiple targets

  • Antibody-drug conjugates if target undergoes internalization

  • Alternative scaffolds if better tissue penetration is needed

• Manufacturing and Stability Considerations:

  • Expression levels in production cell lines

  • Thermal and colloidal stability

  • Resistance to aggregation and degradation

  • Formulation requirements

• Functional Validation Hierarchy:

  • Binding assays → in vitro functional assays → ex vivo assays → in vivo models

  • Comparison with parental MS5 and benchmark antibodies

  • Assessment across multiple cancer models

By systematically addressing these considerations, researchers can develop MS5 variants with enhanced therapeutic properties tailored to specific clinical applications and cancer types.

How should researchers design combination therapy studies involving MS5-Fc antibody?

Designing effective combination therapy studies involving MS5-Fc antibody requires careful consideration of multiple factors:

• Rational Selection of Combination Partners:

  • Complementary mechanisms of action:

    • Immune checkpoint inhibitors (anti-PD-1/PD-L1) to enhance T-cell responses

    • Agents targeting the tumor microenvironment to overcome immunosuppression

    • Therapies addressing different hallmarks of cancer than MS5-Fc

  • Evidence-based combinations:

    • Similar antibodies like agonistic anti-DR5 (MD5-1) have shown synergistic effects with anti-PD-L1

    • Such combinations increased intratumoral CD8+ T-cell infiltration and activation

• Experimental Design Considerations:

  • Preclinical model selection:

    • Immunocompetent models to evaluate immune-mediated effects

    • Models relevant to target cancer types (breast, lymphoma, leukemia)

    • PDX models for translational relevance

  • Dosing schedule optimization:

    • Sequential vs. concurrent administration

    • Dose-response relationships for each agent

    • Potential for altered pharmacokinetics in combinations

• Comprehensive Endpoint Assessment:

  • Efficacy parameters:

    • Tumor growth inhibition

    • Survival analysis

    • Complete response rates

    • Duration of response

  • Mechanistic investigations:

    • Immune cell infiltration patterns

    • Changes in tumor microenvironment

    • Pharmacodynamic biomarkers

    • Resistance mechanisms

• Study Design Framework:

  Study Phase	Key Elements	Considerations
  Exploratory	- Initial screening of combinations - Dose-finding - Schedule optimization	- Use multiple models - Include monotherapy controls - Assess tolerability
  Mechanism validation	- Detailed analysis of selected combinations - Pharmacodynamic biomarkers - Immune profiling	- Time-course studies - Tissue collection for ex vivo analysis - Single-cell approaches
  Translational	- PDX models - Humanized immune system models - Predictive biomarkers	- Clinical trial design implications - Patient selection strategies - Resistance mechanisms

• Toxicity Assessment:

  • Evaluation of potential synergistic toxicities

  • Immune-related adverse events

  • Strategies to mitigate toxicity while preserving efficacy

By following this systematic approach, researchers can design rigorous combination therapy studies that maximize the therapeutic potential of MS5-Fc antibody and provide a strong foundation for clinical translation.

How might next-generation technologies enhance the therapeutic potential of antibodies like MS5-Fc?

Several emerging technologies could significantly enhance the therapeutic potential of antibodies like MS5-Fc:

• Advanced Antibody Engineering Platforms:

  • FCRL5-directed CAR-T cells demonstrate how antibody-derived targeting domains can be repurposed for cellular therapies

  • Integration of interleukin-15 (IL-15) into CAR designs enhances T cell persistence and function

  • Similar approaches could be applied to MS5 targeting domains

• Novel Fc Engineering Approaches:

  • Dual Fc architectures containing two Fc domains significantly enhance avidity for Fc receptors

  • Cross-isotype antibodies combining elements of different antibody classes expand the range of effector cells that can be recruited

  • Structure-guided design of Fc domains with optimized FcγR binding profiles

• Precision Glycoengineering:

  • Production of afucosylated antibodies with enhanced ADCC activity

  • Site-specific incorporation of defined glycan structures

  • Glycan modifications tailored to specific effector functions or tissue targeting

• Multispecific Antibody Formats:

  • Bispecific antibodies combining MS5 binding with immune checkpoint inhibition

  • Trispecific formats engaging multiple targets simultaneously

  • Immune cell engagers bringing effector cells into proximity with tumor cells

• Antibody-Drug Conjugate Technologies:

  • Site-specific conjugation technologies

  • Novel payloads with improved therapeutic index

  • Stimulus-responsive linkers for controlled drug release

• Computational Approaches:

  • AI-driven antibody optimization

  • Molecular dynamics simulations to predict binding and stability

  • In silico prediction of immunogenicity risks

These technological advances could transform MS5-Fc from a conventional therapeutic antibody into a versatile platform for developing next-generation cancer immunotherapies with enhanced efficacy, improved safety profiles, and broader applicability across cancer types.

What are the challenges and strategies for translating MS5 antibody findings from preclinical models to clinical applications?

The translation of MS5 antibody from preclinical models to clinical applications faces several challenges that require strategic approaches:

• Target Expression and Biology Differences:

  • Challenge: Human tumors may exhibit different patterns of target expression than xenograft models

  • Strategy: Extensive validation of target expression in human tumor biobanks and comparison with preclinical models

  • Approach: Development of companion diagnostics to identify patients with appropriate target expression

• Immune System Differences:

  • Challenge: Human immune effector functions may differ from murine systems, affecting ADCC/ADCP activities

  • Strategy: Testing in humanized immune system models and ex vivo studies with human immune cells

  • Approach: Fc engineering tailored to human FcγR affinities and polymorphisms

• Pharmacokinetics and Biodistribution:

  • Challenge: Differences in half-life and tissue penetration between preclinical models and humans

  • Strategy: Incorporation of half-life extension technologies like LS mutations (Met428Leu/Asn434Ser)

  • Approach: Use of mathematical modeling to predict human PK based on preclinical data

• Safety and Toxicity Predictions:

  • Challenge: Off-target binding may differ between species

  • Strategy: Extensive tissue cross-reactivity studies with human tissues

  • Approach: Implementation of dose-escalation strategies with careful safety monitoring

• Biomarker Development:

  • Challenge: Identifying predictive biomarkers of response for patient selection

  • Strategy: Parallel development of biomarker assays during preclinical testing

  • Approach: Utilization of multiple biomarker modalities (IHC, flow cytometry, circulating markers)

• Clinical Trial Design Considerations:

  • Challenge: Selecting appropriate cancer indications, endpoints, and combination approaches

  • Strategy: Design trials informed by mechanism of action and preclinical efficacy data

  • Approach: Adaptive trial designs with biomarker-guided cohort expansion

By systematically addressing these challenges, researchers can enhance the probability of successfully translating MS5 antibody from promising preclinical results to effective clinical therapies for cancer patients.

What are the recommended protocols for evaluating MS5-Fc-induced immune cell infiltration in tumor models?

Protocol for Evaluating MS5-Fc-Induced Immune Cell Infiltration in Tumor Models

The following protocol outlines methods for comprehensive assessment of immune cell infiltration following MS5-Fc treatment:

Materials Required:

• MS5-Fc antibody and appropriate control antibodies

• Tumor-bearing mice (models demonstrated with MS5-Fc include breast, lymphoma, and leukemia xenografts)

• Flow cytometry antibodies for immune cell phenotyping

• Immunohistochemistry reagents

• Cell isolation reagents

• RNA isolation and analysis reagents

Procedure:

• Experimental Setup

  • Establish tumors in appropriate mouse models

  • Randomize mice to treatment groups when tumors reach 50-100 mm³

  • Administer MS5-Fc antibody intravenously at established doses (3-10 mg/kg based on previous studies)

  • Include control groups: vehicle, isotype control antibody, positive control antibody (e.g., rituximab for B-cell lymphomas)

• Tissue Collection and Processing

  • Harvest tumors at multiple timepoints (early: 24-48h, mid: 7d, late: 14-21d post-treatment)

  • Process each tumor into three portions:

    • Fix in 10% neutral buffered formalin for histology

    • Flash-freeze for RNA/protein analysis

    • Process into single-cell suspension for flow cytometry

• Flow Cytometric Analysis

  • Prepare single-cell suspensions from tumors using appropriate dissociation protocols

  • Stain cells with fluorescently-labeled antibodies against:

    • Macrophages: CD11b, F4/80, CD68, M1/M2 markers (CD80, CD206)

    • NK cells: NK1.1, CD49b, NKG2D

    • T cells: CD3, CD4, CD8, activation markers (CD69, CD25)

    • B cells: B220, CD19

    • MDSCs: CD11b, Gr-1, Ly6G, Ly6C

  • Analyze by multiparameter flow cytometry

  • Compare infiltration patterns between treatment groups

• Immunohistochemistry/Immunofluorescence

  • Section FFPE tumor tissues (5 μm thickness)

  • Perform IHC/IF for immune cell markers:

    • CD68 or F4/80 for macrophages

    • NKp46 for NK cells

    • CD3, CD8 for T cells

  • Use multiplex immunofluorescence to assess cell-cell interactions

  • Quantify using digital pathology software

  • Map spatial distribution of immune cells relative to tumor cells

• Gene Expression Analysis

  • Extract RNA from tumor samples

  • Perform qRT-PCR or RNA-seq analysis

  • Focus on genes related to:

    • Immune cell markers

    • Chemokines and chemokine receptors

    • Cytokines and inflammatory mediators

    • Immune checkpoint molecules

• Functional Assessment of Infiltrating Cells

  • Isolate immune cells from tumors for ex vivo functional assays

  • Assess cytotoxicity against tumor cells

  • Measure cytokine production

  • Evaluate proliferative capacity

• Data Analysis and Integration

  • Correlate immune cell infiltration with tumor response

  • Compare temporal changes in immune infiltration

  • Integrate flow cytometry, histology, and gene expression data

  • Identify key immune cell populations associated with MS5-Fc efficacy

This comprehensive protocol enables detailed characterization of MS5-Fc-induced immune cell infiltration, providing insights into mechanisms of action and potential biomarkers of response.

What analytical methods are recommended for assessing MS5 antibody interactions with Fc receptors?

Analytical Methods for Assessing MS5 Antibody Interactions with Fc Receptors

Comprehensive assessment of MS5 antibody interactions with Fc receptors requires multiple complementary techniques:

• Surface Plasmon Resonance (SPR)

  • Setup: Immobilize recombinant Fc receptors (FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, FcRn) on sensor chip

  • Measurements:

    • Association and dissociation rate constants (kon, koff)

    • Equilibrium dissociation constant (KD)

    • pH-dependent binding for FcRn interactions

  • Analysis:

    • Compare binding parameters with reference antibodies

    • Assess the impact of Fc modifications on binding kinetics

    • For FcRn, test binding at both pH 6.0 (endosomal) and pH 7.4 (physiological)

• Bio-Layer Interferometry (BLI)

  • Alternative to SPR with similar outputs

  • Example application: MO1 and MO2 antibodies showed high affinity with BA.2 spike RBD, with KD values of 3.3 nM and 2.0 nM

  • Allows for rapid screening of multiple Fc variants against Fc receptor panel

• Cell-Based Reporter Assays

  • Setup: Cells expressing Fc receptors coupled to reporter genes (luciferase)

  • Applications:

    • Measure functional engagement of Fc receptors

    • Assess cellular activation following receptor engagement

    • Screen antibody variants in medium-throughput format

• Flow Cytometry-Based Binding Assays

  • Setup: Cells expressing Fc receptors incubated with MS5 antibody variants

  • Measurements:

    • Binding intensity (MFI)

    • Percentage of positive cells

    • Competition with reference antibodies

  • Applications:

    • Assess binding to native receptors in cell membrane context

    • Evaluate the impact of Fc receptor density on binding

• Analytical Size Exclusion Chromatography (SEC) with Multi-Angle Light Scattering (MALS)

  • Setup: MS5 antibody pre-incubated with soluble Fc receptors

  • Measurements:

    • Formation of antibody-receptor complexes

    • Stoichiometry of binding

  • Applications:

    • Determine how many Fc receptor molecules can bind simultaneously to MS5 antibody

    • Particularly valuable for novel formats like dual Fc antibodies

• Isothermal Titration Calorimetry (ITC)

  • Measurements:

    • Binding affinity

    • Thermodynamic parameters (ΔH, ΔS, ΔG)

    • Binding stoichiometry

  • Applications:

    • Provide complementary data to kinetic measurements

    • Insight into the nature of binding interactions

• Cell-Based Functional Assays

  • ADCC assays: Using NK cells or PBMCs as effectors

  • ADCP assays: Using monocytes or macrophages

  • CDC assays: Using human complement

  • Applications:

    • Correlate Fc receptor binding parameters with functional outcomes

    • Assess the impact of Fc modifications on effector functions

• In vivo Pharmacokinetic Studies

  • Setup: Administration of MS5 antibody variants to appropriate animal models

  • Measurements:

    • Serum half-life

    • Volume of distribution

    • Clearance rates

  • Applications:

    • Assess impact of FcRn binding modifications (e.g., LS mutations)

    • Correlate in vitro binding parameters with in vivo behavior

By combining these analytical methods, researchers can comprehensively characterize MS5 antibody interactions with Fc receptors and rationally design variants with optimized effector functions and pharmacokinetic properties.